Studying the process of brain formation illuminates just how much of development is a series of tiny miracles. Only a few ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has ...

In the past decade, there has been significant interest in studying the expression of our genetic code down to the level of ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

By late 2021, mRNA vaccines had saved an estimated 7.7m lives globally, including most of the 3m Americans whom the Commonwealth Fund, an American health-care charity, estimates were saved by vaccines ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

Senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist, said the results reveal a potential new treatment path — an alternative to surgery, radiation, and chemotherapy — with broad ...

Researchers warn that halting federal contracts for mRNA vaccine research could weaken pandemic preparedness and slow medical advances.

Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.